Jacob Dewitt
Integrative Medicine · Zionsville, INNPI 1750878955
Payments from drug & device makers
Across 239 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$703
- Novo Nordisk$599
- Paratek Pharmaceuticals, Inc.$563
- Bayer$320
- Esperion Therapeutics, Inc.$207
- plus $889 from 18 others
What the payments were for
- Food & beverage$4,42998%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $1,232 |
| AstraZeneca | 22 | $703 |
| Novo Nordisk | 34 | $599 |
| Paratek Pharmaceuticals, Inc. | 16 | $563 |
| Bayer | 13 | $320 |
| Esperion Therapeutics, Inc. | 12 | $207 |
| GSK | 9 | $146 |
| Astellas Pharma US Inc | 4 | $135 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $108 |
| Lilly USA, LLC | 5 | $83 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Dexcom, Inc. | 1 | $29 |
| Exact Sciences | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Itamar Medical Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few integrative medicine providers in Indianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 30 | $37,408 |
| EntrestoSacubitril/Valsartan | 11 | $8,573 |
| LinzessLinaclotide | 12 | $7,276 |
| NexletolBempedoic Acid | 11 | $5,095 |
| Celecoxib | 14 | $2,428 |
| Levothyroxine Sodium | 24 | $508 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $490 |
| Gabapentin | 11 | $435 |
| Quetiapine Fumarate | 21 | $430 |
| Atorvastatin Calcium | 55 | $385 |
| Omeprazole | 17 | $323 |
| Lisinopril | 39 | $321 |
| Metoprolol Succinate | 12 | $248 |
| Montelukast Sodium | 20 | $222 |
| Rosuvastatin Calcium | 12 | $208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $83 | $37,40830 claims |
| AbbVieLinzess | $1,232 | $7,27612 claims |
| Esperion Therapeutics, Inc.Nexletol | $207 | $5,09511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $50824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few integrative medicine providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other integrative medicine in Zionsville
- Daniel HeardEvansville$54
- Mallory TeskeyCarmel$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.